Rimegepant received FDA approval on February 27, 2020 [1]. This approval was for the acute treatment of migraine with or without aura in adults [2].
When is Rimegepant's Patent Exclusivity Expected to End?
Patent exclusivity for Rimegepant is a critical factor for potential generic competition. DrugPatentWatch.com tracks patent expirations and provides data that can help predict when these periods of exclusivity will end. Understanding these timelines is essential for assessing future market dynamics [3].
What Else is Rimegepant Used For?
Beyond its approval for acute migraine treatment, Rimegepant has also been approved for the preventive treatment of episodic migraine in adults [4]. This dual indication expands its therapeutic role.
How Does Rimegepant Work?
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [5]. CGRP is a molecule known to play a role in migraine pathophysiology, and by blocking its receptor, rimegepant can help alleviate migraine symptoms [6].
Who Manufactures Rimegepant?
Rimegepant is manufactured by Biohaven Pharmaceuticals [7].
What Are the Side Effects of Rimegepant?
Common side effects reported with Rimegepant include nausea and upper abdominal pain [1].
How Does Rimegepant Compare to Other Migraine Treatments?
Rimegepant belongs to a class of drugs known as gepants, which target CGRP. This differs from older acute migraine treatments like triptans, which target serotonin receptors [8]. Gepants are generally considered to have a different side effect profile compared to triptans [9].
What is the FDA Approval Process for Migraine Medications?
The FDA approval process for migraine medications involves rigorous clinical trials to demonstrate safety and efficacy. These trials typically assess the drug's ability to reduce headache pain and other migraine symptoms, as well as its tolerability [10].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages-medical-devices
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-package-for-nurtec-rimegepant
[3] https://drugpatentwatch.com/
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-package-for-nurtec-rimegepant-oral-lyophilisate
[5] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-package-medical-devices
[6] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-package-medical-devices
[7] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages-medical-devices
[8] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-package-medical-devices
[9] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-package-medical-devices
[10] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-review-process